Gary Zieziula

Mr. Gary Zieziula has more than 40 years of working experience in the pharmaceutical industry. He has held important positions in many multinational pharmaceutical companies and successfully formed and led teams for commercialization activities in Europe and North America. Mr. Zieziula currently serves as President of Kyowa Kirin's North American subsidiary and head of North America. Kyowa Kirin Corporation is a Japan-based global pharmaceutical company focused on the development and commercialization of antibody drugs in the core therapeutic areas of oncology, kidney disease, central nervous system and immunity. Mr. Zieziula joined the company in 2019. Under his leadership, North America has become the fastest growing region for Kyowa Kirin's global business. Prior to joining Kyowa Kirin, Mr. Zieziula successively served as chief commercial officer and then president of EMD Serono, the North American subsidiary of Merck KGaA Pharmaceuticals, where he promoted the company's successful commercialization of oncology, neurological/immune, fertility and endocrine products in North America, reversing the The downward trend of several products in the North American market strengthened the momentum of market share growth. At the same time, under his leadership, the company's innovative product line has further expanded. Previously, Mr. Zieziula served as a strategic advisor to venture capital firms and pharmaceutical companies on global M&A and product licensing opportunities. Mr. Zieziula has also held key positions at AMAG , Roche , Bristol-Myers Squibb and Merck & Co. pharmaceutical companies. Mr. Zieziula received a bachelor's degree from the State University of New York in the United States and an MBA from Canisius College in the United States.